米托蒽醌联合方案治疗非何杰金淋巴瘤的临床观察

Mitoxantrone combination chemotherapy for 89 cases of non-Hodgkin's lymphomas

目的：观察两组含米托蒽醌联合方案对８９例非何杰金淋巴瘤（ＮＨＬ）的疗效。方法：用ＭｘＣＯＭＢＰ及ＭｘＣＯＭＰ两组方案治疗各期ＮＨＬ，计算ＣＲ率，有效率，χ２及Ｐ值，并以此来判断两组方案的优越性。结果：８９例患者的ＣＲ率为５３．９％，有效率为８６．５％，Ⅰ＋Ⅱ期患者的疗效明显优于Ⅲ＋Ⅳ期患者（Ｐ＜０．０１）；ＭｘＣＯＭＢＰ方案的有效率９３．８％优于ＭｘＣＯＭＰ方案的有效率７８．１％（χ２＝４．７７，Ｐ＜０．０５），对Ⅲ、Ⅳ期及高度恶性患者效果更佳。两组方案的不良反应为恶心、呕吐及骨髓抑制，７５％限于Ⅰ、Ⅱ度，心脏毒性少见。结论：米托蒽醌联合方案是治疗ＮＨＬ的有效方案，平阳霉素可提高米托蒽醌联合方案的疗效。

Purpose: Observing response to 2 chemotherapeutic regimens including Mitoxantrone (Mx) in 89 cases of Non-Hodgkin's Lymphoma (NHL). Method: MxCOMBP and MxCOMP regimens were used and their advantages were judged with complete response rate, response rate by χ2 and P value. Result: CR rate was 53.9% and RR was 86.5% in MxCOMBP and MxCOMP regimens. But the response rate in Ⅰ+Ⅱ stage patients were better than in Ⅲ+Ⅳ stage (P<0.01). The RR of MxCOMBP was much better than MxCOMP (χ2=4.752,P<0.05), especially in Ⅲ,Ⅳ stage and high-grade malignant patients. The side effects were nausea, vomiting and myelosuppresion, but in the great majorrity (75%) of patients they were limited to Ⅰ～Ⅱ grade and the cardiac side effect was rare. Conclusion: Mitoxantrone combination chemotherary may be selected as effective regimen in the treatment of NHL and the Bleomycin can elevate the therapeutic effect of Mitoxantrone combination chemotherapy.